On January 5, Gevo, Inc. GEVO completed its previously announced 1-for-20 stock split needed to maintain the common stock listing on the NASDAQ Capital Markets exchange. Rodman & Renshaw’s Amit Dayal ...
Rodman & Renshaw launched its coverage of Canadian biopharma Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and a $9 price target, citing a potential FDA nod for its lead candidate ...
Rodman & Renshaw downgraded Viracta Therapeutics (VIRX) to Neutral from Buy with a price target of 25c, down from $3.50, after Viracta announced it has elected to close its ongoing pivotal Phase 2 ...
Rodman & Renshaw analyst Elemer Piros initiated coverage of Tharimmune (THAR) with a Buy rating and $17 price target Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks ...
Richtech Robotics Inc. (RR) on Thursday announced a new at-the-market (ATM) equity offering, granting it the ability to sell up to $100 million worth of its Class B common stock. Under the new ...
after the company reported 3Q y/y revenues that were up 28%. In the report, Rodman & Renshaw writes, "Intel (INTC, Market Outperform) reported third quarter 2011 revenues up 28% Y/Y and 9% Q/Q to ...
TipRanks on MSN
MIRA Pharmaceuticals expands stock offering by $15M
An announcement from MIRA Pharmaceuticals, Inc. ( ($MIRA) ) is now available. On December 5, 2025, MIRA Pharmaceuticals, Inc. announced an ...
Rodman & Renshaw initiated coverage on shares of INmune Bio (NASDAQ:INMB – Free Report) in a research report sent to investors on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and ...
LITTLETON, Colo., Sept. 6, 2011 /PRNewswire/ -- Ur-Energy Inc. (TSX:URE, NYSE Amex:URG) ("Ur-Energy" or the "Company") Chairman and Executive Director Jeff Klenda will present an update on the Company ...
THE WOODLANDS, Texas, Nov. 1 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that Alan J. Main, Ph.D., senior vice president of ...
Rodman & Renshaw initiated coverage of Omeros (OMER) with a Buy rating and $9 price target Omeros is a biopharmaceutical company focused on developing innovative therapies for rare diseases and has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results